Youssef, E., Raslan, H., El-Sheikh, S., Riad, S., Mehanna, R., Afifi, M. (2020). EXPRESSION OF TLR7 IN ORAL SQUAMOUS CELL CARCINOMA AND ITS CORRELATION WITH LYMPH NODE METASTASIS (AN IMMUNO-HISTOCHEMICAL STUDY). test, 45(1), 88-92. doi: 10.21608/adjalexu.2020.79946
Engy A. Youssef; Hanaa S. Raslan; Sahar M. El-Sheikh; Sahar E. Riad; Radwa A. Mehanna; Marwa M. Afifi. "EXPRESSION OF TLR7 IN ORAL SQUAMOUS CELL CARCINOMA AND ITS CORRELATION WITH LYMPH NODE METASTASIS (AN IMMUNO-HISTOCHEMICAL STUDY)". test, 45, 1, 2020, 88-92. doi: 10.21608/adjalexu.2020.79946
Youssef, E., Raslan, H., El-Sheikh, S., Riad, S., Mehanna, R., Afifi, M. (2020). 'EXPRESSION OF TLR7 IN ORAL SQUAMOUS CELL CARCINOMA AND ITS CORRELATION WITH LYMPH NODE METASTASIS (AN IMMUNO-HISTOCHEMICAL STUDY)', test, 45(1), pp. 88-92. doi: 10.21608/adjalexu.2020.79946
Youssef, E., Raslan, H., El-Sheikh, S., Riad, S., Mehanna, R., Afifi, M. EXPRESSION OF TLR7 IN ORAL SQUAMOUS CELL CARCINOMA AND ITS CORRELATION WITH LYMPH NODE METASTASIS (AN IMMUNO-HISTOCHEMICAL STUDY). test, 2020; 45(1): 88-92. doi: 10.21608/adjalexu.2020.79946

EXPRESSION OF TLR7 IN ORAL SQUAMOUS CELL CARCINOMA AND ITS CORRELATION WITH LYMPH NODE METASTASIS (AN IMMUNO-HISTOCHEMICAL STUDY)

Alexandria Dental Journal
Article 15, Volume 45, Issue 1, April 2020, Pages 88-92    PDF (239.07 K)
Document Type: Original Article
DOI: 10.21608/adjalexu.2020.79946
Authors
Engy A. Youssef* 1; Hanaa S. Raslan2; Sahar M. El-Sheikh2; Sahar E. Riad2; Radwa A. Mehanna3; Marwa M. Afifi4
1Assistant lecturer in Oral Pathology Department, Faculty of Dentistry, Kafrelsheikh University.
2Professor in Oral Pathology Department, Faculty of Dentistry, Alexandria University.
3Assistant Professor in Physiology Department, Faculty of Medicine, Alexandria University.
4Lecturer in Oral Pathology Department, Faculty of Dentistry, Alexandria University.
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) accounts for most of oral cancers which is about (90%) of all types. OSCC is an important cause of morbidity and mortality worldwide. Early detection; diagnosis and early treatment are still the key points for OSCC patients to improve survival rate and quality of life. Toll like receptors (TLRs), through their role in innate immunity, have been implicated in the pathogenesis of several diseases, including cancer and OSCC is one of these cancers. Nodal metastasis is playing a key role in detecting the prognosis and the outcome. TLR7 is one of the TLRS which is expressed in OSCC, the correlation between the expression of this receptor and the presence of nodal metastasis has been assessed and evaluated as TLR7 may be of great significance in tumors metastasis so can help in prognosis and aid in treatment modalities.
Objectives: The aim of the present study was to evaluate the expression of TLR7 in the specimens of primary tumor tissues of OSCC and correlate it with the lymph node involvement.
Materials and methods: TLR7expression was studied in 50 OSCC cases. The specimens were taken from the primary tumor of 25 cases with positively involved lymph nodes and another 25 cases with negatively involved lymph nodes and 10 normal mucosal tissues taken from OSCC patients and healthy individuals. Immuno-histochemical (IHC) staining was performed using the Labeled Strept-Avidin Biotin complex method (LSAB), using the anti-TLR7 antibody.
Results:TLR7 showed high expression in OSCC cases with positive lymph node metastasis than those with negative lymph node metastasis.
Conclusions: TLR7 expression could be a guiding tool used to detect prognosis in OSCC patients and as an indicator for metastasis
Keywords
Oral squamous cell carcinoma; lymph node metastasis; TLR7; Immunohistochemistry
References
  1. Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017;70:23-8.
  2. Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, et al. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015;137:2060-71.
  3. Rivera C. Essentials of oral cancer. Int J Clin Exp Pathol. 2015;8:11884-94.
  4. Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res. 2008;87:14-32.
  5. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87-108.
  6. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359-86
  7. Luongo de Matos L, Manfro G, Vieira dos Santos R, Stabenow E, Sobroza de Mello E, Alves VAF, et al. Tumor Thickness As A Predictive Factor Of Lymph Node Metastasis And Disease Recurrence In T1n0 And T2n0 Squamous Cell Carcinoma Of The Oral Tongue. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology. 2014.
  8. Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope. 2005;115(4):629-39.
  9. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552-9.
  10. Pasare C, Medzhitov R. Toll-like receptors and acquired immunity. Semin Immunol. 2004; 16:23-6.
  11. Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: Pro-tumorigenic effects and anti-tumor functions. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2013; 1835:144-54.
  12. Lee CC, Avalos AM, Ploegh HL. Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol. 2012; 12:168-79.
  13. Akira S. Toll receptor families: structure and function. Semin Immunol. 2004;16:1-2.
  14. Takeda K, Kaisho T, Akira S. Toll-Like Receptors. Annual Review of Immunology. 2003;21:335-76.
  15. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of singlestranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-9.
  16. Ahn MY, Kwon SM, Cheong HH, Park JH, Lee J, Min SK, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J Oral Pathol Med. 2012;41:540-6.
  17. Syrbu SI, Cohen MB. An enhanced antigen-retrieval protocol for immunohistochemical staining of formalinfixed, paraffin-embedded tissues. Methods Mol Biol. 2011;717:101-10. 
  18. Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student ed. Belmont, Calif.: Wadsworth, Cengage Learning; 2013.
  19. Rosati G, Riccardi F, Tucci A. Use of tumor markers in the management of head and neck cancer. Int J Biol Markers 2000;15(2):179-83.
  20. Guha N, Boffetta P, Wunsch F, V, Eluf NJ, Shangina O, Zaridze D, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol 2007;166(10):1159-73.
  21. Ahmed M.Kabel . Tumor markers of breast cancer: New prospectives. Journal of Oncological Sciences. 2017 April ; 3 (1):5-11.
  22. Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology. 2004;4:499.
  23. Kaczanowska S, Joseph AM, Davila E. TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013;93(6):847-63.
  24. Dajon M, Iribarren K, Cremer I. Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. Immunobiology. 2017;222(1):89-100.
  25. Farzaneh Pakdel1, Firouz Pouralibaba1*, Sina Pakdel2, Reza Khorshidi Khiyavi3, Parisa Falsafi1, Hosein Eslami1 et al . Expression of toll-like receptors in squamous cell carcinoma of the tongue. Scholars Research Library. 2015; 7 (2):20-24
  26. Shiva Solahay Kahnamouii, Firoz Pouralibaba, Farzaneh Pakdel , Mahni Rahkar Farshi, Farrokh Farhady , Homayoon Sadegi Bazargani et al. Expression of The Toll Like Receptor (TLR) 2, TLR4, TLR7 and TLR8 in Squamous Cell Carcinoma of the Human Tongue. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2015;119(3):106.
  27. Ilyar Sheyhidin, Gulnaz Nabi, Ayshamgul Hasim, Rui-Ping Zhang, Julaiti Ainiwaer, Hong Ma . Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol. 2011 August ; 17(32): 3745-3751.
  28. Julien Cherfils-Vicini, Sophia Platonova, Mélanie Gillard, Ludivine Laurans, Pierre Validire, Rafaele Caliandro. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest. 2010;120(4):1285–1297.
  29. Saradiya Chatterjee, Lucile Crozet, Diane Damotte, Kristina Iribarren,Catherine Schramm, Marco Alifano . TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non–Small Cell Lung Cancer. Cancer Research. 2014 septemper ;74(18): 5008–18.
  30. Mee-Young Ahn, Seong-Min Kwon, Hak Hyun Cheong, Jong-Hwan Park Ren WH, Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. Journal of Oral Pathology and Medicine. May 2012; 41(7):540-6.
  31. Marion Dajon, Kristina Iribarren, and Isabelle Cremer. Dual roles of TLR7 in the lung cancer microenvironment. OncoImmunology . March 2015 ;4 (3) :1615.
Statistics
Article View: 265
PDF Download: 459